Ark Therapeutics Group Overview
- Year Founded
-
2001
- Status
-
Private
- Employees
-
58
- Latest Deal Type
-
IPO
- Latest Deal Amount
-
$103M
Ark Therapeutics Group General Information
Description
Operator of a specialty healthcare company intended to discover, develop and commercialize novel viral-based gene therapies and targeted vascular medicines. The company offers specialized adenoviral vector manufacturing and targeted gene therapy delivery platforms, enabling healthcare providers and biopharmaceutical developers to address unmet medical needs in vascular diseases, oncology, and severe tissue-specific conditions through targeted localized treatments.
Contact Information
Website
www.premiervetgroup.co.ukCorporate Office
- 20-22 Wenlock Road
- London N1 7GU
- England, United Kingdom
Corporate Office
- 20-22 Wenlock Road
- London N1 7GU
- England, United Kingdom
Ark Therapeutics Group Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. IPO | 08-Mar-2004 | $103M | Completed | Generating Revenue | ||
| 3. Grant | Completed | Startup | ||||
| 2. Early Stage VC | 01-Sep-2001 | $20.9M | $21M | Completed | Startup | |
| 1. Angel (individual) | 01-Jan-2001 | $150K | $150K | Completed | Startup |
Ark Therapeutics Group Patents
Ark Therapeutics Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20140121160-A1 | Use of vegf in the treatment of retarded fetal growth in pregnancy | Inactive | 29-Oct-2012 | ||
| GB-201116880-D0 | Vector | Inactive | 30-Sep-2011 | ||
| GB-201111218-D0 | Sequence | Inactive | 01-Jul-2011 | ||
| GB-201111219-D0 | Sequence | Inactive | 01-Jul-2011 | ||
| CA-2824689-A1 | Combination therapy for cancer | Active | 18-Jan-2011 | A61K31/7088 |
Ark Therapeutics Group Signals
Ark Therapeutics Group Acquisitions (2)
Ark Therapeutics Group’s most recent deal was a Merger/Acquisition with Premier Vet Alliance for . The deal was made on 05-Feb-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Premier Vet Alliance | 05-Feb-2015 | Merger/Acquisition | Other Services (B2C Non-Financial) | ||
| Lymphatix | 08-Jan-2008 | Merger/Acquisition | Drug Discovery |
Ark Therapeutics Group Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Premier Vet Alliance | Bristol, United Kingdom | 2001 |
Ark Therapeutics Group FAQs
-
When was Ark Therapeutics Group founded?
Ark Therapeutics Group was founded in 2001.
-
Where is Ark Therapeutics Group headquartered?
Ark Therapeutics Group is headquartered in London, United Kingdom.
-
What is the size of Ark Therapeutics Group?
Ark Therapeutics Group has 58 total employees.
-
What industry is Ark Therapeutics Group in?
Ark Therapeutics Group’s primary industry is Drug Discovery.
-
Is Ark Therapeutics Group a private or public company?
Ark Therapeutics Group is a Private company.
-
What is the current valuation of Ark Therapeutics Group?
The current valuation of Ark Therapeutics Group is .
-
What is Ark Therapeutics Group’s current revenue?
The current revenue for Ark Therapeutics Group is .
-
How much funding has Ark Therapeutics Group raised over time?
Ark Therapeutics Group has raised $124M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process